Other news to note for Oct. 3, 2023
Original source here.
Hamburg, Germany-based 3B Scientific GmbH acquired San Diego-based Wallcur LLC, a provider of health care simulation products.
Grand Rapids, Mich.-based Airlife Medical LLC, a North American manufacturer and distributor of consumable medical devices for anesthesia and respiratory care formerly known as Sunmed, closed its acquisition of Alpharetta, Ga.-based Avanos Medical Inc.’s respiratory health business, including the Ballard, Microcuff and product lines. The transaction advances Airlife’s strategy to enhance its portfolio of products in anesthesia and respiratory care and serve as a one-stop source for consumable breathing solutions that support the best patient outcomes.
The Hague, The Netherlands-based Amber Implants BV launched the first-in-human clinical trial for its Vcfix spinal system for patients with vertebral compression fractures.
Bruker Corp., of Billerica, Mass., completed the acquisition of Torrance, Calif.-based Phenomex Inc., a provider of single-cell biology research tools, for $108 million in cash. Bruker reported the agreement to acquire PhenomeX on Aug. 17, 2023.
Herstal, Belgium-based Mdxhealth SA proposed switching to listing its stock solely on Nasdaq, rather than on Nasdaq and Euronext Brussels. In light of the proposal, the company called an extraordinary general shareholders’ meeting to be held on Nov. 3, 2023.
Nano-x Imaging Ltd. (Nanox), of Neve Ilan, Israel, signed a strategic manufacturing agreement with Salt Lake City-based Varex Imaging Corp. Varex will supply X-ray tubes utilizing the Nanox digital X-ray source for the Nanox Arc system. The agreement was entered into after Varex completed, over the last several months, an assessment of Nanox’s digital X-ray source.
Neuronetics Inc., of Malvern, Pa. reported that it has drawn down the remaining $22.5 million from its credit facility with SLR Capital Partners LLC. The funds will be used to bolster the company’s balance sheet in a non-dilutive manner and support the ongoing execution of its strategy.
Binyamina, Israel-based Oncohost Ltd. reported a collaboration with Shanghai Henlius Biotech’s subsidiary, Hengenix Biotech (Henlius USA). Henlius will utilize Oncohost’s Prophet platform to identify exploratory, correlative biomarkers for patients recruited in its comprehensive phase III trial (NCT05468489). The trial is evaluating the efficacy and safety of Serplulimab plus chemotherapy (carboplatin – etoposide) in previously untreated U.S.-based patients with Extensive-Stage Small Cell Lung Cancer.
Ranfac Corp., of Avon, Mass., completed the acquisition and ownership of Cervos Medical LLC. Operating as a fully owned subsidiary of Ranfac Corp, Cervos will build upon their foundation in the orthobiologic industry with expanded access to Ranfac’s resources, expertise, network and ability to scale operations to meet emerging opportunity and demand.
Whitmore Lake, Mich-based Trace Medical LLC reported a long-term distribution agreement with San Jose, Calif.-based Outset Medical Inc. to rent the Tablo Hemodialysis system to home medical equipment (HME) providers. As part of this agreement, Trace Medical will leverage its national distribution network to offer HME providers exclusive access to rent Tablo and meet the growing demand of dialysis patients seeking treatment at home.
Vela Diagnostics GmBH, of Hamburg, Germany, reported a research collaboration with SRL Inc, a subsidiary of H.U. Group Holdings Inc., to facilitate the distribution of Vela’s Sentosa SQ HIV-1 genotyping assay kit to Japanese health care and diagnostic institutions.